Although antiretroviral therapy (ART) can reduce viremia to below the limit of detection and
allow persons living with HIV-1 (PLWH) to lead relatively normal lives, viremia rebounds …

Combination antiretroviral therapy (ART) for HIV-1 infection reduces plasma virus levels to
below the limit of detection of clinical assays. However, even with prolonged suppression of …

The development of persistent cellular reservoirs of latent human immunodeficiency virus
(HIV) is a critical obstacle to viral eradication since viral rebound takes place once anti …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of
infected individuals (here termed 'elite controllers'), despite the presence of a replication …

Brain microglia (MG) may serve as a human immunodeficiency virus 1 (HIV) reservoir and
ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet …

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure,–.
Curative strategies that target the reservoir are being tested, and require accurate, scalable …

Human immunodeficiency virus type 1 (HIV-1) eradication is prevented by the establishment
on infection of cellular HIV-1 reservoirs that are not fully characterized, especially in genital …

A latent reservoir for HIV-1 in resting CD4+ T lymphocytes precludes cure. Mechanisms
underlying reservoir stability are unclear. Recent studies suggest an unexpected degree of …

Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …